Pilot translational study of dietary vitamin C supplementation in Barrett's esophagus

Diseases of the Esophagus

Volumn 23, Issue 3, 2010, Pages 271-276

  Babar, M ^a   Abdel Latif, M M M ^a   Ravi, N ^a   Murphy, A ^a   Byrne, P J ^a   Kelleher, D ^a   Reynolds, J V ^a  

^a ST JAMES S HOSPITAL   (Ireland)

Author keywords

Barrett's esophagus; Cytokines; NF B; Vitamin C

Indexed keywords

ASCORBIC ACID; CYTOKINE; GROWTH FACTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; INTERLEUKIN 8; VASCULOTROPIN; ANTIOXIDANT;

ADULT; AGED; ARTICLE; BARRETT ESOPHAGUS; CANCER PREVENTION; CLINICAL ARTICLE; COLORIMETRY; CYTOKINE PRODUCTION; DIET SUPPLEMENTATION; ENDOSCOPIC BIOPSY; ESOPHAGEAL ADENOCARCINOMA; FEMALE; HUMAN; IMMUNOASSAY; INFLAMMATION; INTESTINE METAPLASIA; MALE; PILOT STUDY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; VITAMIN INTAKE; CLINICAL TRIAL; COHORT ANALYSIS; METABOLISM; MIDDLE AGED; PATHOLOGY;

ADULT; AGED; ANTIOXIDANTS; ASCORBIC ACID; BARRETT ESOPHAGUS; COHORT STUDIES; CYTOKINES; DIETARY SUPPLEMENTS; FEMALE; HUMANS; MALE; MIDDLE AGED; NF-KAPPA B; PILOT PROJECTS;

EID: 77953235022     PISSN: 11208694     EISSN: 14422050     Source Type: Journal    
DOI: 10.1111/j.1442-2050.2009.01027.x     Document Type: Article

References (33)

1. Aldulaimi D, Jankowski J. Barrett's esophagus: an overview of the molecular biology. Dis Esophagus 1999; 12: 177-80.
2. Pera M, Cameron A J, Trastek V F, Carpenter H A, Zinsmeister A R. Increasing incidence of adenocarcinoma of the esophagus and esophagogastric junction. Gastroenterology 1993; 104: 510-13.
3. Carton E, Mulligan E D, Keeling P W, Tanner A, McDonald G, Reynolds J V. Specialized intestinal metaplasia: analysis of prevalence, risk factors and association with gastrooesophageal reflux disease. Br J Surg 2000; 87: 362-73.
4. Caygill C P, Watson A, Lao-Sirieix P, Fitzgerald R C. Barrett's oesophagus and adenocarcinoma. World J Surg Oncol 2004; 2: 12.
5. Botterweck A A, Schouten L J, Volovics A, Dorant E, van Den Brandt P A. Trends in incidence of adenocarcinoma of the oesophagus and gastric cardia in ten European countries. Int J Epidemiol 2000; 29: 645-54.
6. Peters C J, Fitzgerald R C. Systematic review: the application of molecular pathogenesis to prevention and treatment of oesophageal adenocarcinoma. Aliment Pharmacol Ther 2007; 25: 1253-69.
7. Das D, Chilton A P, Jankowski J. Chemoprevention of oesophageal cancer and the AspECT trial. Recent Results Cancer Res 2009; 181: 161-9.
8. Chen F, Castranova V, Shi X, Demers L M. New insights into the role of nuclear factor-kappaB, a ubiquitous transcription factor in the initiation of diseases. Clin Chem 1999; 45: 7-17.
9. Lenardo M J, Baltimore D. NF-kappa B: a pleiotropic mediator of inducible and tissue-specific gene control. Cell 1989; 58: 227-9.
10. Yamamoto Y, Gaynor R B. Therapeutic potential of inhibition of the NF-kappaB pathway in the treatment of inflammation and cancer. J Clin Invest 2001; 107: 135-42.
11. Fitzgerald R C. Review article: Barrett's oesophagus and associated adenocarcinoma - a UK perspective. Aliment Pharmacol Ther 2004; 20 (Suppl 8): 45-9.
12. O'Riordan J M, Abdel-latif M M, Ravi N et al. Proinflammatory cytokine and nuclear factor kappa-B expression along the inflammation-metaplasia-dysplasia-adenocarcinoma sequence in the esophagus. Am J Gastroenterol 2005; 100: 1257-64.
13. Abdel-Latif M M, O'Riordan J, Windle H J et al. NF-kappaB activation in esophageal adenocarcinoma: relationship to Barrett's metaplasia, survival, and response to neoadjuvant chemoradiotherapy. Ann Surg 2004; 239: 491-500.
14. Konturek P C, Nikiforuk A, Kania J, Raithel M, Hahn E G, Mühldorfer S. Activation of NFkappaB represents the central event in the neoplastic progression associated with Barrett's esophagus: a possible link to the inflammation and overexpression of COX-2, PPARgamma, and growth factors. Dig Dis Sci 2004; 49: 1075-83.
15. Jenkins G J, Harries K, Doak S H et al. The bile acid deoxycholic acid (DCA) at neutral pH activates NF-κB and induces IL-8 expression in esophageal cells in vitro. Carcinogenesis 2004; 25: 317-23.
16. Abdel-Latif M M, Kelleher D, Reynolds J V. Potential role of NF-kappaB in esophageal adenocarcinoma: as an emerging molecular target. J Surg Res 2009; 153: 172-80.
17. Aidoo A, Lyn-Cook L E, Lensing S, Wamer W. Ascorbic acid (vitamin C) modulates the mutagenic effects produced by an alkylating agent in vivo. Environ Mol Mutagen 1994; 24: 220-8.
18. Johnson L F, DeMeester T R. Twenty-four hour pH monitoring of the distal esophagus. A quantitative measure of gastroesophageal reflux. Am J Gastroenterol 1974; 62: 325-32.
19. Comstock G W, Norkus E P, Hoffman S C, Xu M W, Helzlsouer K J. Stability of ascorbic acid, carotenoids, retinol, and tocopherols in plasma stored at -70 degrees C for 4 years. Cancer Epidemiol Biomarkers Prev 1995; 4: 505-7.
20. Kallner A, Hartmann D, Hornig D. Steady-state turnover and body pool of ascorbic acid in man. Am J Clin Nutr 1979; 32: 530-9.
21. Levine M, Conry-Cantilena C, Wang Y et al. Vitamin C pharmacokinetics in healthy volunteers: evidence for a recommended dietary allowance. Proc Natl Acad Sci U S A 1996; 93: 3704-9.
22. Madrigal L, Lynch S, Feighery C, Weir D, Kelleher D, O'Farrelly C. Flow cytometric analysis of surface major histocompatibility complex class II expression on human epithelial cells prepared from small intestinal biopsies. J Immunol Methods 1993; 158: 207-14.
23. Baeuerle P A, Henkel T. Function and activation of NF-kappa B in the immune system. Annu Rev Immunol 1994; 12: 141-79.
24. Barnes P J, Karin M. Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 1997; 336: 1066-71.
25. Carr A C, Frei B. Toward a new recommended dietary allowance for vitamin C based on antioxidant and health effects in humans. Am J Clin Nutr 1999; 69: 1086-107.
26. Bjelakovic G, Nikolova D, Simonetti R G, Gluud C. Antioxidant supplements for prevention of gastrointestinal cancers: a systematic review and meta-analysis. Lancet 2004; 364: 1219-28.
27. Blot WJ, Li J Y, Taylor P R et al. Nutrition intervention trials in Linxian, China: supplementation with specific vitamin/mineral combinations, cancer incidence, and disease-specific mortality in the general population. J Natl Cancer Inst 1993; 85: 1483-92.
28. Creagan E T, Moertel C G, O'Fallon J R et al. Failure of high-dose vitamin C (ascorbic acid) therapy to benefit patients with advanced cancer. A controlled trial. N Engl J Med 1979; 301: 687-90.
29. Moertel C G, Fleming T R, Creagan E T, Rubin J, O'Connell M J, Ames M M. High-dose vitamin C versus placebo in the treatment of patients with advanced cancer who have had no prior chemotherapy. A randomized double-blind comparison. N Engl J Med 1985; 312: 137-41.
30. Hanson KM, Clegg RM. Bioconvertible vitamin antioxidants improve sunscreen photoprotection against UV-induced reactive oxygen species. J Cosmet Sci 2003; 54: 589-98.
31. Levine M, Rumsey S C, Daruwala R, Park J B, Wang Y. Criteria and recommendations for vitamin C intake. JAMA 1999; 281: 1415-23.
32. Bowie A G, O'Neill L A. Vitamin C inhibits NF-kappa B activation by TNF via the activation of p38 mitogen-activated protein kinase. J Immunol 2000; 165: 7180-8.
33. Brennan P, O'Neill L A. Inhibition of NF kappa B activity by oxidative processes in intact cells mechanism of action of pyrolidine dithiocarbamate and diamide. Biochem Soc Trans 1996; 24: 3S.